Dr Timothy Crook, Consultant Medical Oncologist
Dr Timothy Crook
Consultant Medical Oncologist
Dr Timothy Crook MBBS, BSc, PhD, CCT(Med Onc)
Consultant Medical Oncologist
Dr Timothy Crook
Consultant Medical Oncologist MBBS, BSc, PhD, CCT(Med Onc)
Dr Crook is a recommended Consultant Medical Oncologist
Areas of expertise
- Chemotherapy
- Bladder cancer
- Breast disease
- Kidney cancer
- Skin cancer
Recommendations for Dr Crook
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon
❝Dr Timothy Crook is a specialist in medical oncology with research interests in personalised oncology and novel treatments for resistant cancers. He is a valued member of the London Breast Institute multi-disciplinary team.❞
byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon
❝Dr Timothy Crook is a specialist in medical oncology with research interests in personalised oncology and novel treatments for resistant cancers. He is a valued member of the London Breast Institute multi-disciplinary team.❞
Make an appointment
Address
-
LOC at Chelsea
102 Sydney Street, Chelsea, London, SW3 6NJ
-
LOC - Leaders in Oncology Care
95-97 Harley Street, London, W1G 6AF
-
Sydney Street Outpatients and Diagnostics Centre
102 Sydney Street, London, SW3 6NJ
-
The Harley Street Clinic
35 Weymouth Street, London, W1G 8BJ
-
The Princess Grace Hospital
42-52 Nottingham Place, London, W1U 5NY
-
The Wellington Hospital
Wellington Place, St John's Wood, London, NW8 9LE
About Dr Timothy Crook
GMC number: 4735788
Year qualified: 2000
Place of primary qualification: University of London
Areas of expertise
- Medical Oncology
- Immunotherapy
- Breast Cancer
- Melonoma
- Renal cancer
- Urological oncology
Professional memberships
Articles by Dr Timothy Crook
102pencyclopedic tumour analysis (eta) guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers
111pmtor inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers
Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the resilient trial
Multi-analyte liquid biopsies for treatment guidance in advanced refractory cancers: findings of the liquid impact trial
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Hallmark circulating tumor-associated cell clusters signify 230 times higher one-year cancer risk
Circulating ensembles of tumor associated cells: a redoubtable new systemic hallmark of cancer
Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging
